Article Text

Download PDFPDF
About antifragility and the challenge of dealing with endovascular therapy trials that fail to show a positive result

Statistics from


  • Twitter @johanna_ospel

  • Contributors MG: conceptualization, drafting, and critical revision of the manuscript. JMO: drafting and critical revision of the manuscript and figures.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests MG reports grants from Stryker, personal fees from Stryker, personal fees from Medtronic, personal fees from Microvention, and personal fees from Mentice, outside of the submitted work. MG has a patent systems of acute stroke diagnosis licensed to GE Healthcare and a patent systems of intracranial access licensed to Microvention.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.